Cancer immunoediting by the innate immune system in the absence of adaptive immunity
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Cancer immunoediting is the process whereby immune cells protect against cancer formation by sculpting the immunogenicity of developing tumors. Although the full process depends on innate and adaptive immunity, it remains unclear whether innate immunity alone is capable of immunoediting. To determine whether the innate immune system can edit tumor cells in the absence of adaptive immunity, we compared the incidence and immunogenicity of 3'methylcholanthrene-induced sarcomas in syngeneic wild-type, RAG2(-/-), and RAG2(-/-)x γc(-/-) mice. We found that innate immune cells could manifest cancer immunoediting activity in the absence of adaptive immunity. This activity required natural killer (NK) cells and interferon γ (IFN-γ), which mediated the induction of M1 macrophages. M1 macrophages could be elicited by administration of CD40 agonists, thereby restoring editing activity in RAG2(-/-)x γc(-/-) mice. Our results suggest that in the absence of adaptive immunity, NK cell production of IFN-γ induces M1 macrophages, which act as important effectors during cancer immunoediting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In line with these findings, microbes may reverse the resistance to immunotherapy through reactivation of IFN-ɤ signaling pathways.”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“IFN-ɤ, an important cytokine involved in antitumor immunity, could upregulate MHC expression on tumor cells and M1 macrophages and facilitate the recognition and elimination of transformed cells (91, 92).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“…for macrophages that is consistent with studies performed almost 40 yr ago, when it was shown that activated macrophages from infected mice (Hibbs et al., 1971) could kill syngeneic transformed murine embryonic fibroblasts, but not primary nontransformed murine embryonic fibroblasts (Hibbs…”
BackgroundTakahashi, K., & Yamanaka, S. (2006) · Cell · doi:10.1016/j.cell.2006.07.024 · Cited by 26,673 · cited 1×
“Using the 3 methylcholanthrene (MCA) model of sarcomagenesis, we previously found that the immune system in WT mice could edit tumors more effectively than the immune system in RAG2 / mice (which lack adaptive immunity; Shankaran et al., 2001; Takahashi and Yamanaka, 2006), but we did not assess whether tumors from RA…”
MethodCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Self-citationMonocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190 · cited 4×
“M1 macrophages are activated classically via IFN- and function in the removal of intracellular pathogens (Gordon and Taylor, 2005).”
BackgroundResultInfluentialThe Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Self-citationThe Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Self-citationIFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896 · cited 13×
“Tumor induction by MCA was performed as previously described (Smyth et al., 2000; Shankaran et al., 2001).”
BackgroundMethodResultInfluentialSelf-citationAlternative Activation of Macrophages: An Immunologic Functional Perspective
Martinez, F. O., Helming, L., & Gordon, S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132532 · Cited by 2,745 · cited 1×
“…characterized by quantitative PCR, using markers known to be associated with an M1-type phenotype (TNF and inducible nitric oxide synthase [iNOS]; Martinez et al., 2009) or with an M2-type phenotype (arginase and epithelial cadherin [eCAD]), growth arrest–specific gene 3 (Gas3; Ghassabeh et al.,…”
MethodDistinct role of macrophages in different tumor microenvironments
Lewis, C. E., & Pollard, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4005 · Cited by 2,225 · cited 2×
“…that these macrophages were classically activated (Gordon and Taylor, 2005) M1 macrophages and performed immunophenotyping to detect the presence of tumor-associated M1 or M2 macrophages, known to have anti- or pro-tumor functions, respectively (Lewis and Pollard, 2006; Sica et al., 2008).”
BackgroundRAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement
Shinkai, Y. (1992) · Cell · doi:10.1016/0092-8674(92)90029-c · Cited by 2,150 · cited 1×
“Genotyping was performed using PCR (for IL-2R c, following The Jackson Laboratories protocol [http://jaxmice.jax.org/strain/003174.html]) or by Southern blot for RAG2 (Shinkai et al., 1992).”
Method
Cited by
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
“Moreover, CX3CR-1 patrolling monocytes inhibit metastatic progression through the recruitment of NK cells to the metastatic site, and then NK cell-derived IFN-γ reprograms macrophages into a tumoricidal effector macrophage state (O’Sullivan et al. 2012).”
Mittal, D., Gubin, M. M., Schreiber, R. D., & Smyth, M. J. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.01.004 · Cited by 1,471
Self-citationRole of tumor microenvironment in tumorigenesis
Wang, M., Zhao, J., Zhang, L., Wei, F., Lian, Y., Wu, Y., Gong, Z., Zhang, S., Zhou, J., Cao, K., et al. (2017) · Journal of Cancer · doi:10.7150/jca.17648 · Cited by 1,404
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
The Molecular Mechanism of Natural Killer Cells Function and Its Importance in Cancer Immunotherapy
Paul, S., & Lal, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01124 · Cited by 825
Metadata
- Authors
- O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C. M., Arthur, C., White, J. M., Uppaluri, R., Andrews, D. M., Ngiow, S. F., Teng, M. W. L., Smyth, M. J., Schreiber, R. D., & Bui, J. D.
- Affiliations
- University of California San Diego (US)
- Department of Pathology, University of California at San Diego, La Jolla, CA 92093 1
- University of Brescia (IT)
- Washington University in St. Louis (US)
- Center for Immunology, Department of Pathology and Immunology 3 and 4
- The University of Melbourne (AU)
- Corresponding author
- Bui, Jack D.
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2012-08-27
- Volume
- 209
- Issue
- 10
- Pages
- 1869-1882
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3457735
- OpenAlex
- W2144577255
- Cited by
- 348
- References
- 58
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 24 · 2023: 31 · 2022: 22 · 2021: 30 · 2020: 29 · 2019: 25 · 2018: 32 · 2017: 30 · 2016: 27 · 2015: 23 · 2014: 21 · 2013: 29 · 2012: 6
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion, cc-by-nc-sa)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion, public-domain)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
- Funders
- Cancer Research Institute
- Concern Foundation
- Hartwell Foundation (CA157885)
- Ludwig Institute for Cancer Research
- Cancer Research Coordinating Committee
- National Institutes of Health (CA157885)
- Medical Research Council
- National Health and Medical Research Council
- National Cancer Institute (CA 107527, CA128893, K08CA128893, K08CA090403, R01CA043059, R01CA157885, CA-43059, R37CA043059, R01CA107527, CA157885)
- National Center for Research Resources (C06RR012466)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- cancer immunoediting, innate immunity, natural killer cells, interferon-gamma, M1 macrophages, CD40 agonist, Rag2 knockout mice, tumor immunogenicity, adaptive immunity
- MeSH terms
- Animals, Histocompatibility Antigens Class II, DNA-Binding Proteins, Immunity, Innate, Interferon-gamma, Killer Cells, Natural, Macrophages, Neoplasms, Phenotype, Sarcoma, Transplantation, Isogeneic, Mice, Knockout, CD40 Antigens, Genetic Predisposition to Disease, Cell Line, Tumor, Mice, Interleukin Receptor Common gamma Subunit, Adaptive Immunity, Immunomodulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer immunoediting by the innate immune system in the absence of adaptive immunity. https://app.cochat.ai/papers/10.1084/jem.20112738
- The paper
- O’Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C. M., Arthur, C., White, J. M., Uppaluri, R., Andrews, D. M., Ngiow, S. F., Teng, M. W. L., Smyth, M. J., Schreiber, R. D., & Bui, J. D. (2012). Cancer immunoediting by the innate immune system in the absence of adaptive immunity. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20112738
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.